Shilpa Bioscience secures European distribution partnership for recombinant human albumin
Indian biopharmaceutical company Shilpa Biocare has established a strategic commercial supply agreement with Finland’s Orion Corporation, positioning its innovative recom-
binant human albumin for European market entry ahead of the BIO Boston conference.
The partnership between Shilpa Biocare Private Limited, a subsidiary of Shilpa Medicare Limited, and Orion Corporation represents a significant advancement in albumin therapeutic development, addressing critical limitations of traditional human-derived albumin through advanced biotechnology platforms.
Strategic partnership framework
Under the commercial agreement, Orion Corporation will acquire exclusive distribution, marketing and sales rights for Shilpa’s recombinant human albumin across European markets. The arrangement includes development and regulatory milestone payments flowing to Shilpa, establishing a structured progression towards market commercialisation.
Technical innovation in albumin production
Shilpa’s recombinant human albumin utilises a robust non-human expression system for manufacturing, delivering enhanced safety profiles, improved scalability, and virus-free production capabilities. This biotechnological approach directly addresses key limitations associated with conventional human-derived albumin, particularly concerning viral contamination risks and supply chain constraints.
The plasma protein serves multiple therapeutic applications, with the recombinant variant offering superior manufacturing consistency and safety assurance compared to traditional extraction methods.
Market positioning and strategic outlook
“We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,” said Satu Ahomäki, EVP Generics and Consumer Health at Orion Corporation. “Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.”
Madhav Bhutada, Managing Director of Shilpa Biocare, emphasised the partnership’s significance: “Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market.”
